Protocols

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

Carl Decicco, Bristol-Myers Squibb

Carl Decicco, Bristol-Myers Squibb

Bristol-Myers Squibb has turned to Paris-based microbiome expert Enterome for its latest immuno-oncology partnership. The biotech landed a $15 million upfront and unspecified, research support and milestones to begin work on new biomarkers and therapeutics for cancer. Bristol-Myers is looking to the gut for new insights into the way the microbiome influences resistance and response to immunotherapies, like its blockbuster checkpoint Opdivo. “Enterome’s focus on target identification and validation along with their significant experience in microbiome research can help to advance our goal to improve outcomes for patients treated with immunotherapies,” said Carl Decicco, head of discovery at Bristol-Myers Squibb.

San Francisco-based Glycomine has raised a $12 million A round led by Sanderling Ventures and supported by Chiesi Ventures “as well as existing high net worth individuals and patients.” The biotech plans to use that money for its work on a substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1).

Germany’s MorphoSys AG raised $126 million through a private offering. “The funds we have raised will allow us to further develop our proprietary portfolio, for example taking our anti-CD19 antibody MOR208 into a pivotal phase 3 study in diffuse large B cell lymphoma (DLBCL), an indication with high medical need,” said CEO Simon Moroney. “The new funds significantly strengthen our ability to execute our strategy.”

Shares of Flexion Therapeutics $FLXN dropped about 10% this morning, after the company reported that it priced an offering of 3.6 million shares at $18 each.

Amgen and its partners at Allergan have handed in their BLA for their biosimilar of Roche’s Avastin. ABP 215 is the furthest along of four biosimilar projects they’ve been working on. This follows an application from rivals at Mylan and Biocon, as Roche stares down generic competition to a trio of its top drugs. Avastin earned $6.7 billion for Roche last year.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017